Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $127.18

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $130.7273.

A number of analysts recently issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $142.00 target price on shares of TransMedics Group in a research report on Tuesday, October 14th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Stifel Nicolaus assumed coverage on TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price for the company. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Needham & Company LLC raised TransMedics Group from a “hold” rating to a “buy” rating and set a $148.00 price objective for the company in a research report on Thursday.

Institutional Trading of TransMedics Group

Hedge funds have recently added to or reduced their stakes in the stock. OneDigital Investment Advisors LLC lifted its position in TransMedics Group by 52.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after acquiring an additional 2,065 shares during the period. Principal Financial Group Inc. lifted its position in TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after acquiring an additional 5,480 shares during the period. Vontobel Holding Ltd. acquired a new stake in TransMedics Group during the 1st quarter worth approximately $291,000. New York State Teachers Retirement System lifted its position in TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after acquiring an additional 14,200 shares during the period. Finally, Peregrine Capital Management LLC lifted its position in TransMedics Group by 3.4% during the 1st quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company’s stock worth $4,601,000 after acquiring an additional 2,250 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Trading Up 1.2%

NASDAQ:TMDX opened at $130.52 on Monday. The stock has a market cap of $4.45 billion, a P/E ratio of 67.63 and a beta of 2.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $145.50. The stock has a 50-day simple moving average of $115.94 and a 200-day simple moving average of $115.84.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million during the quarter, compared to analysts’ expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business’s revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.